Group 1: LeMo Technology IPO - LeMo Technology plans to globally offer 5.5556 million shares, with 555,600 shares for Hong Kong and 5 million shares for international investors [1] - The offering period is from November 25 to November 28, with a maximum offer price of HKD 40.00 per share and an entry fee of approximately HKD 4,040.35 [1] - The total expected fundraising amount is HKD 186 million, with a net amount of HKD 147 million, aimed at expanding service network coverage, enhancing technology, increasing brand awareness, and general corporate purposes [1] Group 2: Jinyan Gaoling New Materials IPO - Jinyan Gaoling New Materials intends to globally offer 24.3 million shares, with 2.43 million shares for Hong Kong and 21.87 million shares for international investors, plus an over-allotment option of 3.645 million shares [2] - The offering period is also from November 25 to November 28, with a maximum offer price of HKD 7.30 per share and an entry fee of approximately HKD 3,686.82 [2] - The total expected fundraising amount is HKD 177 million, with a net amount of HKD 124 million, to be used for deep processing projects, establishing a research center, working capital, and repaying bank loans [2] Group 3: Mingyu Pharmaceutical Listing Application - Mingyu Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with joint sponsors including Morgan Stanley, Bank of America Securities, and CITIC Securities [3] - The company focuses on developing tumor therapies based on ADC platforms and PD-1/VEGF bispecific antibodies, with 13 candidate products in its pipeline, 10 of which are in clinical stages [3] - The listing aligns with the trend of innovative drugs and aims to capitalize on the company's pipeline and commercialization potential [3] Group 4: Kewang Pharmaceutical Listing Application - Kewang Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [4] - The company is a clinical-stage biopharmaceutical firm focused on developing next-generation cancer therapies through an understanding of the tumor microenvironment [4] - Its core product, ES102, is an advanced hexavalent OX40 agonist, currently one of only two OX40 agonist candidates in clinical development [4]
乐摩科技、金岩高岭新材开启港股招股；明宇制药、科望医药递表港交所丨港交所早参